Journal article
Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus
FB Vincent, R Kandane-Rathnayake, AY Hoi, L Slavin, JD Godsell, AR Kitching, J Harris, CL Nelson, AJ Jenkins, A Chrysostomou, ML Hibbs, PG Kerr, M Rischmueller, F Mackay, EF Morand
Lupus | SAGE PUBLICATIONS LTD | Published : 2018
Abstract
Introduction: We examined the clinical relevance of urinary concentrations of B-cell–activating factor of the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) in systemic lupus erythematosus (SLE). Methods: We quantified urinary BAFF (uBAFF) by enzyme-linked immunosorbent assay in 85 SLE, 28 primary Sjögren syndrome (pSS), 40 immunoglobulin A nephropathy (IgAN) patients and 36 healthy controls (HCs). Urinary APRIL (uAPRIL) and monocyte chemoattractant protein 1 (uMCP-1) were also quantified. Overall and renal SLE disease activity were assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000. Results: uBAFF was detected in 12% (10/85) of SLE ..
View full abstractGrants
Funding Acknowledgements
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors wish to thank the French Society of Rheumatology for its support. F.M. is a recipient of fellowships from the NHMRC of Australia. E.F.M. was supported by the Kim Jolly Lupus Research Trust, and the Monash Lupus Database has received support from Arthritis and Osteoporosis Victoria, and unrestricted educational grants from GlaxoSmithKline, UCB, AstraZeneca and Eli Lilly Australia.